MNTS Stock: $76M Cash, No Debt, and the Ownership Test
Momentus says its cash position has jumped to about $76 million with no debt. The real question is whether Vigoride progress can become revenue before share-count math absorbs the upside.
OpenSearch
Find research, discussions, posts, companies, and topics.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
14Results11Tickers
Refine results
Recent Searches
Signed-in searches appear here after you use search.
Trending
XORTX Therapeutics Inc.: the filing proof gates that matter nowWilliams Companies: natural-gas infrastructure cash flow has to outlast capex and rate riskAurora Cannabis (ACB): the medical-cannabis turnaround trying to outrun dilutionAbbVie Inc. (ABBV) Coverage Bootstrap: Skyrizi and Rinvoq-led biopharma transition after HumiraAmbev (ABEV) Coverage Bootstrap: beer-led scale, Brazil execution, pricing discipline, and cash returnsAsbury Automotive Group (ABG) Coverage Bootstrap: dealership scale, service profit, F&I scrutiny, and leverage disciplineAble View Global (ABLV) Coverage Bootstrap: China beauty brand management, channel concentration, controlled voting, and listing riskABM Industries (ABM) Coverage Bootstrap: facility services scale, margin recovery, WGNSTAR integration, and labor execution
Top Tickers
Popular Tags
Tag facets appear after tag usage counts are rebuilt.
Results
Save searchLatest indexed results
Showing public results only.
DVLT $2B structured financing explained for beginners
A beginner-friendly translation of Datavault AI's $2.0B structured financing term sheet, including term sheet status, dilution, tranches, the $25M payment, share-value math, and shareholder proof gates.
OpenDVLT institutional flow check: financing signal, not a supply-crunch thesis
A source-backed Datavault AI analysis that separates the real May 2026 institutional financing signal from unsupported dark-pool, hedge-fund, bank-upgrade, and supply-crunch claims.
OpenDVLT $2B HELMEX Mystery: Is the Address Really the Red Flag?
A beginner-friendly, fact-based DVLT brief on HELMEX, the UK address controversy, the non-binding $2B term sheet, the $25M payment, dilution, and board rights.
OpenDVLT 8-K: $2B headline, $25M cash test
Datavault AI's June 4 Form 8-K turns the structured financing story into a cash, dilution, control, and approval proof gate.
OpenAIIA: the AI shell has cash, a clock, and no target yet
AI Infrastructure Acquisition Corp. is a newly public SPAC with $140.5 million in trust, $1.1 million of cash outside trust, no operating revenue, no announced target and an April 6, 2027 deadline. The current thesis is trust math, sponsor incentives and futur
OpenAFJK: 1.04 million public shares left to carry a $1.5 billion hydrogen deal
Aimei Health is no longer a healthcare-search story. It is a high-risk de-SPAC watch where a small remaining SPAC trust is trying to close a $1.5 billion all-share United Hydrogen transaction.
OpenAEXA: $351M in trust, no operating business, and a deadline that matters
AEXA is not a business yet. It is a NYSE-listed SPAC with $351.4 million in trust, $0.3 million of cash outside trust, no selected target as of March 31, 2026, and public shareholder economics that turn on redemption value, sponsor incentives and the future de
OpenActivate Energy: The $230 Million Oil-and-Gas SPAC Still Hunting for a Deal
Activate Energy has no wells, no operating revenue, and no target yet. The source-backed story is a $230.6 million trust account, a December 2027 deal clock, oil-and-gas sponsor ambition, and a structure where Class A shares and warrants carry very different r
OpenADAC: the $230 million blank check that still has to find a real company
American Drive Acquisition Company gives investors a documented SPAC trust, a defense/logistics/technology/AI search mandate, and no operating target yet. The useful question is whether the eventual deal beats the promote, warrants, redemption risk, and deadli
OpenAverin Capital (ACAA): the $284 million health-tech blank check with no company yet
ACAA gives investors a real trust account, a health-and-technology sponsor story, and almost no operating company to analyze. The question is whether that blank check becomes a disciplined de-SPAC or another dilution machine.
OpenAbony Acquisition Corp. I (AACO) Coverage Bootstrap: SPAC trust value before any target thesis
Official-source baseline for Abony Acquisition Corp. I using SEC submissions, SEC XBRL companyfacts, the FY2025 10-K, Q1 FY2026 10-Q, final IPO prospectus, and IPO-related 8-Ks.
OpenArmada Acquisition Corp. III (AACI) Coverage Bootstrap: SPAC trust value before any target thesis
Official-source baseline for Armada Acquisition Corp. III using SEC submissions, SEC XBRL companyfacts, the FY2025 10-K, Q1 FY2026 10-Q, final IPO prospectus, and IPO-related 8-Ks.
OpenArtius II Acquisition (AACB) Coverage Bootstrap: SPAC cash shell, not an operating-company thesis yet
Official-source baseline for Artius II Acquisition Inc. using SEC submissions, SEC companyfacts, the FY2025 10-K, Q1 FY2026 10-Q, and final IPO prospectus.
Open